HomeNewsScreenerChartsMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help

New Elite Feature: Screen & Chart at the same time

Learn More
Market News Market Pulse Stocks News ETF News Crypto News

Taysha Gene Therapies, Inc.

Contributing Author

Recent Articles by Taysha Gene Therapies, Inc.

May-06
Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update TSHA GlobeNewswire
May-01
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) TSHA GlobeNewswire
Apr-29
Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6 TSHA GlobeNewswire
Apr-27
Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting TSHA GlobeNewswire
Apr-03
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) TSHA GlobeNewswire
Mar-19
Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update TSHA GlobeNewswire
Mar-12
Taysha Gene Therapies to Release Full-Year 2025 Financial Results and Host Conference Call and Webcast on March 19 TSHA GlobeNewswire
Mar-06
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) TSHA GlobeNewswire
Feb-06
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) TSHA GlobeNewswire
Jan-06
Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome TSHA +7.57% GlobeNewswire
Dec-05
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) TSHA +7.92% TSHA GlobeNewswire
Nov-04
Taysha Gene Therapies Reports Third Quarter 2025 Financial Results and Provides Corporate Update TSHA GlobeNewswire
Oct-28
Taysha Gene Therapies to Release Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 4 TSHA GlobeNewswire
Oct-16
Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome TSHA -7.09% TSHA GlobeNewswire
Oct-09
Taysha Gene Therapies Presents New Supplemental Data Analysis from Part A of the REVEAL Phase 1/2 Trials for TSHA-102 in Rett Syndrome at the 54th CNS Annual Meeting TSHA GlobeNewswire
Oct-03
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) TSHA -7.14% TSHA GlobeNewswire
Oct-02
Taysha Gene Therapies Announces FDA Breakthrough Therapy Designation and Provides Positive Regulatory Update on TSHA-102 in Rett Syndrome TSHA +53.46% GlobeNewswire
Sep-05
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) TSHA GlobeNewswire
Aug-12
Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update TSHA +5.43% GlobeNewswire
Aug-05
Taysha Gene Therapies to Release Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 12 TSHA GlobeNewswire
Aug-01
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) TSHA GlobeNewswire
Jul-03
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) TSHA GlobeNewswire
Jun-06
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) TSHA GlobeNewswire
Jun-03
Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program TSHA GlobeNewswire
May-28
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants TSHA +12.70% GlobeNewswire
May-28
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants TSHA +12.70% TSHA -6.33% GlobeNewswire
May-28
Taysha Gene Therapies Announces Pivotal Part B Trial Design Details for TSHA-102 in Rett Syndrome Enabled by IRSF Natural History Data and Positive Clinical Data from Part A of the REVEAL Adult/Adolescent and Pediatric Trials Evaluating TSHA-102 TSHA +12.70% TSHA -6.33% GlobeNewswire
May-15
Taysha Gene Therapies Reports First Quarter 2025 Financial Results and Provides Corporate Update TSHA +8.02% GlobeNewswire
May-08
Taysha Gene Therapies to Release First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15 TSHA +10.53% GlobeNewswire
May-02
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) TSHA +7.05% GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)